多发性骨髓瘤随机对照试验15年间终点使用情况:系统综述
该系统综述检索了2005至2019年多发性骨髓瘤随机对照试验,共纳入151项研究,评估主要终点使用情况。结果显示以总生存(OS)为主要终点的试验仅占11.3%,且从2005-2009年的28.5%降至2015-2019年的5.5%,生活质量作为主要终点仅占2%。
要点
- 仅11.3%的骨髓瘤随机对照试验以总生存为主要终点。
- 总生存作为主要终点的比例从28.5%降至5.5%。
- 生活质量作为主要终点仅占2%,使用率极低。
核心结论
- 过去15年多发性骨髓瘤随机对照试验中以总生存为主要终点的使用减少。
- 替代终点使用普遍,但替代终点并不完美,需持续评估。
研究设计与样本
- 系统综述,检索Pubmed、Embase和Cochrane数据库。
主要发现
- 主要终点为总生存的研究17项(11.3%),无进展生存或事件定义终点91项(60.3%),基于缓解的终点44项(29.1%)。
- 生活质量作为主要终点仅3项(2%)。
- 总生存作为主要终点的比例从2005-2009年的28.5%降至2015-2019年的5.5%。
临床怎么用
- 解读骨髓瘤随机对照试验时需注意主要终点多为替代终点,应谨慎对待基于替代终点的治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Surrogate endpoints are being used more frequently in randomized controlled trials, even though they do not consistently corelate with patient outcomes. We systemically evaluated the use of surrogate endpoints in multiple myeloma randomized controlled trials over the past 15 years. We searched three databases (Pubmed, Embase, Cochrane) for multiple myeloma randomized controlled trials from January 1, 2005 to December 30, 2019. The primary outcome of our study was the proportion of randomized controlled trials that used overall survival as their primary endpoint. Secondary outcomes included the use of surrogate endpoints, and trends over time, and whether they differed based on study sponsorship. We included 151 randomized controlled trials in our analysis. The primary endpoint was overall survival (OS) in 17 (11.3%) of studies, progression free survival (PFS) or event-defined endpoints in 91 studies (60.3%) and response-based endpoints in 44 studies (29.1%). Quality of life was a primary endpoint in only three studies (2%). The use of OS as a primary endpoint decreased from 28.5% of trials from 2005 to 2009 to 5.5% from 2015 to 2019. There has been a decrease in the clinically meaningful endpoint of OS over the past 15 years in multiple myeloma randomized controlled trials. Use of quality of life as a primary endpoint remains exceedingly low. It remains paramount to recognize that the use of surrogate endpoints is imperfect, and care based upon them requires constant physician and patient re-analysis.
引用
- Mohyuddin GR, Koehn K, Abdallah AO, et al. Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review. Am J Hematol. 2021. PMID: 33735453. doi:10.1002/ajh.26166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。